GLP-1 Receptor Agonist Market to reach USD 55.8 billion by 2032, Says Graphical Research Powered by GMI
13 juin 2023 17h30 HE | Graphical Research
Selbyville, Delaware, June 13, 2023 (GLOBE NEWSWIRE) -- GLP-1 Receptor Agonist Market size is estimated to amass USD 55.8 billion by 2032. The industry is set to observe notable growth driven...
ARC logo.png
Gestational Diabetes Treatment Market In Asia Pacific Is Relied Upon To Observe Quicker Development Forecast Till 2030 Analysis Covid-19 Impact: Acumen Research And Consulting
16 juin 2021 12h16 HE | Acumen Research and Consulting
LOS ANGELES, June 16, 2021 (GLOBE NEWSWIRE) -- Gestational diabetes is a type of diabetes that can develop during pregnancy in women who don’t already have diabetes. Gestational diabetes occurs when...
Sirona Biochem Releases Quarterly Financial Results
29 juin 2012 09h00 HE | Sirona Biochem Corp.
VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 29, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB) announced today it has released its quarterly financial...
Synaptic Digital
VIDEO From GI Dynamics and Synaptic Digital: Select U.K. Centres Offer New Treatment for Type 2 Diabetes
11 juin 2012 03h00 HE | Synaptic Digital a Definition 6 Company
LEXINGTON, Mass. and BERKSHIRE, England, June 11, 2012 (GLOBE NEWSWIRE) -- Diabetes affects 3.7 million people in the United Kingdom (U.K.) and another 7 million people are currently at risk for...
Washington, DC Weigh
Washington, DC Weight Loss Surgeons Discuss New Link Between Obesity Surgery and Diabetes Treatment
16 mai 2012 05h09 HE | Bluepoint Surgical Group
WASHINGTON, DC--(Marketwire - May 16, 2012) - Thanks to two recent studies published in The New England Journal of Medicine, researchers and surgeons have established a tangible link between...
Sirona Biochem Announces Diabetes Preclinical Results in Chronic Study
29 févr. 2012 09h00 HE | Sirona Biochem Corp.
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Feb. 29, 2012) - Sirona Biochem Corp. (TSX VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB), announced today its lead compound for the treatment of Type 2...